Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
CTSO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $1.61
Previous CloseN/A
Volume86.19K
Average Volume (3M)81.08K
Market Cap
$61.88M
Enterprise Value$68.40M
Total Cash (Recent Filing)$1.35M
Total Debt (Recent Filing)$172.50K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 06, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding62,500,000
10 Day Avg. Volume68,137
30 Day Avg. Volume81,084
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.42
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda-3.46
Forecast
1Y Price Target
$1.00Price Target Upside3.09% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Cytosorbents News
PremiumCompany Announcements
Cytosorbents Corp Reports Strong Growth Amid Challenges
PremiumCompany Announcements
CytoSorbents Corporation Reports Strong 2024 Performance
PremiumCompany Announcements
CytoSorbents Reschedules Earnings Release to March 2025
PremiumCompany Announcements
CytoSorbents Delays Earnings Release to March 25, 2025
---
Bulls Say, Bears Say
Bulls Say
Product LaunchThe launch of PuriFi, a novel hemoperfusion pump, continues to go well with many evaluations ongoing.
Product Revenue GrowthProduct revenues increased by 25% year-over-year and 6% quarter-over-quarter, driven by a 28% increase in direct sales outside of Germany and a 22% increase in global distributor sales.
Regulatory ApprovalThe regulatory approval of DrugSorb-ATR in the U.S. and Canada could make it the first device indicated for the removal of antithrombotic agents during cardiac surgery in these markets.
Bears Say
Commercial ReorganizationShort-term disruptions could impact topline revenues in the first quarter of 2025 due to the commercial reorganization in Germany.
Declining Gross MarginThe company's blended product gross margin for the quarter decreased to 61%, compared to 72% in 3Q23 and 75% in 2Q24.
Earnings PerformanceThe company reported revenues and net loss that were below consensus estimates, with $9.2M in product revenues and a net loss of $0.14 per share.
---
Ownership Overview
6.97% Insiders
6.87% Mutual Funds
16.91% Other Institutional Investors
65.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.70 and its highest was $1.61 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $61.88M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is May 06, 2025 which is in 31 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Mar 31, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.065 by $0.035.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.05.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,500,000 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.065. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
---
Cytosorbents Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (3.09% Upside)
$1.00 (3.09% Upside)
Insider Transactions
Bought Shares
Worth $32.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.57%
12-Months-Change
Fundamentals
Return on Equity
-120.52%
Trailing 12-Months
Asset Growth
-10.55%
Trailing 12-Months
Company Description
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
---
CTSO Company Deck
---
CTSO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant product revenue growth, healthy gross margins, and progress towards regulatory approval for DrugSorb-ATR, along with a strengthened financial position. However, challenges such as flat growth in Germany, financial restatements, and a temporary sales disruption were also noted. Overall, the positive aspects slightly outweigh the negative ones.Read More>---
CTSO Stock 12 Month Forecast
Average Price Target
$1.00
▲(3.09% Upside)
Technical Analysis
Best Analysts Covering CTSO
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
+3.73%
reiterated a buy rating 3 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of +3.73% per trade.
---